Wednesday, January 29, 2025

 

  • Tirzepatide, FDA, and Compounding: Understanding the Current …

    2 days ago · The removal of tirzepatide from the drug shortage list of the Food and Drug Administration (FDA) list in late 2024 marked a significant turning point for compounders in both 503A and 503B industries.…

  • FDA to continue enforcement discretion on compounded tirzepatide

    5 days ago · This applies to situations where: The compounded product is similar to a commercially available drug Bulk drug substances are used for compounding tirzepatide …

  • Big Pharma has already raised the prices of hundreds of drugs this year Story by Bruce Gil • 13h

     Big Pharma has already raised the prices of hundreds of drugs this year

    Wednesday, January 15, 2025

     

    Lilly sues two medical spas over copycat weight-loss drugs

    2 days ago — Compounding facilities create medicines by combining, mixing or altering drug ingredients. Federal regulations allow compounded versions to be sold to meet ...

     

    Weight Loss Drug Compounding Enforcement Unlikely to ...

    6 days ago — Lawsuits and enforcement actions against pharmaceutical compounders producing copies of popular diabetes and weight loss drugs, such as semaglutide ...

     

    California Pharmacy Board delays vote on compounded ...

    4 days ago — “The BOP's proposed regulations will deny access to compounded drugs that people with chronic illnesses rely on. Cancer patients undergoing chemo and people ...

     

    Pharmacy Alert: FDA Issues Final Interim Guidances ...

    2 days ago — On January 7, 2025, FDA released Guidances on compounding using bulk drug substances for both 503A pharmacies and 503B outsourcing facilities.

     

    Under New Policy, FDA Will Cut Off 'Interim' Compounding ...

    7 days ago — FDA will limit the drug substances that can be compounded by 503A and 503B outsourcing facilities after being proposed for, but not yet approved for, ...

     

    “ The FTC released its second interim report on pharmacy benefit managers on Tuesday, claiming that CVS Caremark, Express Scripts and OptumRx dramatically markup specialty generic drugs to affiliated pharmacies, reaping $7.3 billion in excess revenue.

    Tuesday, January 14, 2025

     On Monday, the FDA published the blog, “FDA Spearheads Global Efforts on Informal Markets and Substandard/Falsified Medical Products.” This blog is the latest in the “From A Global Perspective” series and discusses the FDA’s role in leading WHO efforts to address knowledge gaps regarding the global distribution of substandard and falsified medical products through informal/unregulated markets.

     Today, the FDA’s Center for Veterinary Medicine issued a Dear Veterinarian letter alerting practitioners to the possibility of burns associated with the use of Megadyne grounding pads in animal surgical patients.

    Wednesday, January 8, 2025

     

    Tuesday, January 7, 2025

     

     

    FDA Warns Six Sellers of Unapproved Seizure Drugs for Animals

    Today, the U.S. Food and Drug Administration posted warning letters sent to six firms selling unapproved drugs that claim to treat and control seizures in dogs and cats.

    The unapproved products were sold on the firm’s websites, social media pages and Amazon shops without a prescription or other veterinary oversight. Animal drugs used to treat and control seizures are not safe for animal use except under the professional supervision of a licensed veterinarian because a veterinarian’s specialized training and experience is needed to properly diagnose the condition and manage the health of animals with seizure disorders. Many health problems can cause seizures in animals, including genetic disorders, anemia, head trauma, liver disease, diabetes, cancer and exposure to toxins.

    Read More Button